As companies across the off-patent industry experience mixed fortunes in 2020 – with many firms having suffered adverse effects from the COVID-19 pandemic even in spite of short-term increases in demand enjoyed earlier in the year – Hikma has reported first-half sales and profits “ahead of our initial expectations,” with operating profit rising by 25% to $297m on sales up by 8% at $1.132bn.
Hikma’s First-Half Profits Leap By A Quarter
As Sales Ahead By Almost A Tenth, Boosted By Injectables
Hikma has seen its reported operating profit jump by a quarter in the first half of 2020, as a lift from its injectables business helped to drive up turnover by almost a tenth.
